CC
TVRD

Courier Capital’s Tvardi Therapeutics TVRD Stock Holding History

Courier Capital’s Portfolio TVRD Stock Details TVRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-278
Closed -$215K – 305
2019
Q2 		$215K Hold
278
– – 0.03% 272
2019
Q1 		$196K Hold
278
– – 0.03% 285
2018
Q4 		$130K Sell
278
-55
-17% -$35.5K 0.02% 251
2018
Q3 		$287K Hold
333
– – 0.04% 232
2018
Q2 		$230K Hold
333
– – 0.03% 259
2018
Q1 		$149K Hold
333
– – 0.02% 285
2017
Q4 		$147K Buy
+333
New +$152K 0.02% 287

Other funds holding TVRD

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCP
Rho Capital Partners New York $20.4M AUM
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
C
Chescapmanager Baltimore, Maryland $1.12B AUM 67.49% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DGI
Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return
EMG
ETF Managers Group Summit, New Jersey $3.1B AUM 17.12% 1-Year Est. Return

Courier Capital's TVRD Position: Q3 2019 in Review

Courier Capital sold out of Tvardi Therapeutics (TVRD) in Q3 2019, closing a stake of 278 shares — an estimated $215K sold.

Courier Capital first reported a position in TVRD in Q4 2017 and held it in 7 quarters. The position peaked at $287K in Q3 2018. 144 funds tracked by Wall St. Rank hold TVRD as of Q3 2019.

  • Courier Capital reported no remaining Tvardi Therapeutics position as of Q3 2019 after selling out during the quarter.
  • Courier Capital sold 278 Tvardi Therapeutics shares in Q3 2019, an estimated $215K.
  • Courier Capital first reported a position in Tvardi Therapeutics in Q4 2017 and held it in 7 quarters.
  • Courier Capital's Tvardi Therapeutics position peaked at $287K in Q3 2018.
  • 144 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q3 2019.

Based on Courier Capital's 13F filing for Q3 2019, filed 4 Oct 2019.